SAFETY AND EFFICACY OF ADALIMUMAB THERAPY FOR TREATMENT OF BEHCET’S DISEASE-RELATED UVEITIS IN SOHAG UNIVERSITY HOSPITAL

Document Type : Original articles: include clinical trials, interventional research, Basic researches and clinically relevant laboratory investigations

Authors

Ophthalmology dept., Faculty of Medicine, Sohag Univ. Sohag, Egypt

Abstract

Purpose: To determine whether the biologic medication Adalimumab is safe and effective in treating Behcet's uveitis. Methods: An observational prospective cohort study was conducted at the Ophthalmology department of Sohag University Hospital in Sohag, Egypt. Forty eyes of adult patients with full Behçet's disease associated uveitis were included in the study. Visual acuity, anterior chamber cells, vitreous cells, and macular thickness were assessed using optical coherence tomography (OCT) and fluorescence angiography (FA) at 1, 3, and 6 months after therapy started. Results: The mean age was 37.64 ± 9.44 years, with 71.4% of the subjects being males. Evaluation of visual acuity after six months of therapy showed substantial improvement relative to baseline. Furthermore, the slit lamp microscopy evaluation of the anterior chamber cell grading system after six months demonstrated substantial progress, with over two-thirds of cases achieving a grade of (0), in contrast to no instances at baseline. Optical coherence tomography revealed a substantial reduction in retinal thickness after six months of therapy compared to baseline measurements (257.8 ± 80.37 and 339.75 ± 147.52 μm). Conclusion: Our findings show that adalimumab is a safe and effective treatment for uveitis caused by Behçet's disease.

Keywords

Files

Share

How to cite

Statistics